AZN News and Press, AstraZeneca PLC From 02/19/24

Application based on results from the TROPION-Lung01 phase 3 trial If approved, Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan may be the first TROP2 directed antibody drug conjugate for patients with lung cancer Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (L...

2024-02-18 02:05:00 ET Summary LianBio plans to stop all its operations by the end of 2024 and will distribute a $4.80 dividend/share ($528M) to its shareholders. Yiviva signed a memorandum of understanding with AstraZeneca China for an R&D collaboration at AstraZeneca’...

Approval based on FLAURA2 results which showed TAGRISSO plus chemotherapy extended median progression-free survival by nearly 9 months vs. standard of care AstraZeneca’s TAGRISSO ® (osimertinib) with the addition of chemotherapy has been approved in the US for the trea...

2024-02-15 15:00:53 ET Summary Aurinia Pharmaceuticals Inc. stock price dropped 25% after underwhelming Q4 and full-year 2023 results. Sales of Lupkynis, indicated for lupus nephritis and the company's only commercial product, have failed to meet expectations. Aurinia has init...

2024-02-13 12:00:57 ET Summary Despite higher-than-expected inflation, stock markets remained largely unaffected, with the Dow Jones, Nasdaq, and S&P 500 Indices ignoring the news. Inflation for all items increased by 3.4%, with the shelter index accounting for two-thirds of t...

2024-02-13 09:47:09 ET Citigroup Inc (C) C is trading DOWN for the last 4 days, and it at trading at $52.62 with volume of 4,254,783 and a one day change of $-1.30 (-2.41%). Citigroup Inc has a 52-week low of 38.17 and a 52-week high of $57.95. The business's 50-day moving average p...

A look at the top 10 most actives in the United States Beamr Imaging Ltd. (BMR) rose 371.6% to $9.95 on volume of 154,937,988 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) rose 0.7% to $4.34 on volume of 137,498,905 shares Arm Holdings plc (ARM) rose 29.3% to $148.97 on volume...

2024-02-13 05:50:00 ET Weight-loss drugs are hot. Just look at the recent performances of Eli Lilly (NYSE: LLY) , which won U.S. approval in November for Zepbound, and Novo Nordisk (NYSE: NVO) , which markets Ozempic and Wegovy. Lilly's share price has soared more than 115% ...

2024-02-13 00:50:00 ET Summary Let's take a look at the landscape for GLP-1 drug development (including the drugs that target associated hormones). Novo Nordisk has had a spectacular success with semaglutide (Ozempic/Wegovy), and its effects on weight loss have been established to...

2024-02-12 21:01:27 ET More on Bristol-Myers Squibb Company , Eli Lilly, etc. Pfizer Stock: It's Time To Buy The Dip Pfizer Is A Great Investment Over The Next Decade; Buy Will Eli Lilly and Company Become A Trillion-Dollar Baby? RayzeBio ticks higher af...